EP1.04-04 Pembrolizumab-Induced Fatal Encephalopathy
نویسندگان
چکیده
منابع مشابه
Fatal encephalopathy in glandular fever.
In 1931, Epstein and Dameshek reported a case of meningo-encephalitis complicating glandular fever and in the same year Johansen described a similar case. From 1940 onwards there were a number of reports of individual cases, or small groups of cases, with one or other of the central nervous system complications now known to occur in this disease. Such reports came mainly from North America and ...
متن کاملFatal encephalopathy complicating lymphoid interstitial pneumonia.
The case is reported of a young woman who suffered from lymphoid interstitial pneumonia. Involvement of the brain by what appeared to be an identical pathological process led to her death, and the orbital tissues were also involved at one stage. The cause of this condition is unknown, but the hypotheses are put forward that it may represent one facet of delayed hypersensitivity or that a slow v...
متن کاملFatal Ifosfamide-Induced Metabolic Encephalopathy in Patients with Recurrent Epithelial Ovarian Cancer: Report of Two Cases
Central nervous system (CNS) toxicity has been reported in approximately 10-30% of patients receiving intravenous infusions of ifosfamide. Encephalopathy is a rare but serious CNS adverse reaction in these patients, and although usually transient and reversible, may cause persistent neurological dysfunction or death. Clinical features range from fatigue and confusion to coma and death. Although...
متن کاملValproic acid-induced hyperammonemic encephalopathy – a potentially fatal adverse drug reaction
BACKGROUND A patient with an early diagnosed epilepsy Valproic acid is one of the most widely used antiepileptic drugs. Hyperammonemic encephalopathy is a rare, but potentially fatal, adverse drug reaction to valproic acid. CASE DESCRIPTION A patient with an early diagnosed epilepsy, treated with valproic acid, experienced an altered mental state after 10 days of treatment. Valproic acid seru...
متن کاملPembrolizumab
The development of the cytotoxic T-lymphocyte-associated protein 4 inhibitor ipilimumab and its approval in 2011 for the treatment of metastatic melanoma has heralded a new era in immuno-oncology. Subsequently, novel agents against the programmed death receptor 1 (PD-1)/programmed death receptor ligand 1 (PD-L1) axis have shown significant activity in melanoma and a variety of other tumor types...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Thoracic Oncology
سال: 2019
ISSN: 1556-0864
DOI: 10.1016/j.jtho.2019.08.2120